EE04752B1 - Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine - Google Patents
Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamineInfo
- Publication number
- EE04752B1 EE04752B1 EEP200000068A EEP200000068A EE04752B1 EE 04752 B1 EE04752 B1 EE 04752B1 EE P200000068 A EEP200000068 A EE P200000068A EE P200000068 A EEP200000068 A EE P200000068A EE 04752 B1 EE04752 B1 EE 04752B1
- Authority
- EE
- Estonia
- Prior art keywords
- antibody
- hybridoma producing
- monoclonal antibody
- monoclonal
- integrin
- Prior art date
Links
- 210000004408 hybridoma Anatomy 0.000 title 1
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 206010005042 Bladder fibrosis Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5506097P | 1997-08-08 | 1997-08-08 | |
PCT/US1998/016439 WO1999007405A1 (en) | 1997-08-08 | 1998-08-07 | TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6 |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200000068A EE200000068A (et) | 2000-10-16 |
EE04752B1 true EE04752B1 (et) | 2006-12-15 |
Family
ID=21995323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200000068A EE04752B1 (et) | 1997-08-08 | 1998-08-07 | Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine |
Country Status (23)
Country | Link |
---|---|
US (5) | US20020004482A1 (hu) |
EP (3) | EP1930022B1 (hu) |
JP (2) | JP2001513333A (hu) |
KR (1) | KR100586202B1 (hu) |
CN (1) | CN1267224A (hu) |
AT (3) | ATE511850T1 (hu) |
AU (1) | AU739283B2 (hu) |
BR (1) | BR9814040A (hu) |
CA (1) | CA2297736A1 (hu) |
CY (2) | CY1110462T1 (hu) |
CZ (1) | CZ299768B6 (hu) |
DE (2) | DE69840113D1 (hu) |
DK (2) | DK1504764T3 (hu) |
EE (1) | EE04752B1 (hu) |
ES (3) | ES2364703T3 (hu) |
HU (1) | HU228900B1 (hu) |
IL (2) | IL134288A0 (hu) |
NZ (2) | NZ515955A (hu) |
PL (2) | PL199014B1 (hu) |
PT (3) | PT1930022E (hu) |
RU (1) | RU2221589C2 (hu) |
TR (2) | TR200202323T2 (hu) |
WO (1) | WO1999007405A1 (hu) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962643A (en) * | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
NZ515955A (en) * | 1997-08-08 | 2003-04-29 | Univ California | Hybridoma producing a monoclonal antibody against beta-6 integrin |
CA2370814C (en) * | 1999-04-22 | 2010-07-06 | Biogen, Inc. | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
DE19929410A1 (de) * | 1999-06-26 | 2000-12-28 | Merck Patent Gmbh | Inhibitoren des Integrins avß6 |
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
AUPR230500A0 (en) * | 2000-12-22 | 2001-01-25 | University Of Newcastle Research Associates Limited, The | A method of modulating map kinase mediated cellular activity and agents useful in same |
ATE409047T1 (de) * | 2001-04-30 | 2008-10-15 | Lilly Co Eli | Humanisierte antikörper |
ME00804B (me) | 2002-03-13 | 2012-03-20 | Biogen Idec Inc | Anti-alpha v beta 6 antitela |
US20040048312A1 (en) * | 2002-04-12 | 2004-03-11 | Ronghao Li | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
AU2005229015C1 (en) * | 2004-04-02 | 2013-01-17 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
US8795668B2 (en) * | 2005-12-23 | 2014-08-05 | The Regents Of The University Of Michigan | Methods for treating pulmonary fibrosis |
EP2046374A4 (en) | 2006-07-10 | 2010-05-05 | Biogen Idec Inc | COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS |
AU2007348941B2 (en) * | 2006-08-03 | 2011-08-04 | Medimmune Limited | Antibodies directed to alphaVbeta6 and uses thereof |
CA2665885A1 (en) * | 2006-10-19 | 2008-12-04 | The Regents Of The University Of California | Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6 |
US8679485B2 (en) | 2007-08-02 | 2014-03-25 | Gilead Biologics, Inc. | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
KR101046317B1 (ko) * | 2008-07-04 | 2011-07-05 | 이종대 | 조력발전 방법 및 그 장치 |
US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
EP2456460A4 (en) | 2009-07-24 | 2013-02-20 | Univ California | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING INEGRINE V ASSOCIATED DISEASES |
JP2013502435A (ja) * | 2009-08-21 | 2013-01-24 | ギリアド バイオロジクス,インク. | 線維性肺疾患の処置のための方法および組成物 |
SG2014004816A (en) | 2009-08-21 | 2014-03-28 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
RU2015108348A (ru) * | 2010-02-04 | 2015-07-20 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
CN104220094A (zh) | 2012-02-17 | 2014-12-17 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
EP2784511A1 (en) | 2013-03-27 | 2014-10-01 | Universität Zürich | Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma |
JP6104312B2 (ja) * | 2014-06-19 | 2017-03-29 | 日東電工株式会社 | 組織再生促進剤 |
JP2020531521A (ja) | 2017-08-22 | 2020-11-05 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗アルファ(v)ベータ(6)抗体を含有する医薬組成物及び投薬計画 |
CN114828887A (zh) | 2019-12-05 | 2022-07-29 | 思进公司 | 抗-αVβ6抗体和抗体-药物偶联物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5654270A (en) * | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
AU628910B2 (en) | 1988-12-20 | 1992-09-24 | La Jolla Cancer Research Foundation | Polypeptide-polymer conjugates active in wound healing |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
US5770565A (en) * | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
US6492332B1 (en) * | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
DE69531187T2 (de) * | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
NZ515955A (en) * | 1997-08-08 | 2003-04-29 | Univ California | Hybridoma producing a monoclonal antibody against beta-6 integrin |
-
1998
- 1998-08-07 NZ NZ515955A patent/NZ515955A/xx not_active IP Right Cessation
- 1998-08-07 BR BR9814040-0A patent/BR9814040A/pt not_active Application Discontinuation
- 1998-08-07 DK DK04022921T patent/DK1504764T3/da active
- 1998-08-07 US US09/130,870 patent/US20020004482A1/en not_active Abandoned
- 1998-08-07 NZ NZ502546A patent/NZ502546A/en not_active IP Right Cessation
- 1998-08-07 CN CN98807892A patent/CN1267224A/zh active Pending
- 1998-08-07 PL PL341029A patent/PL199014B1/pl unknown
- 1998-08-07 DE DE69840113T patent/DE69840113D1/de not_active Expired - Lifetime
- 1998-08-07 EP EP08004714A patent/EP1930022B1/en not_active Expired - Lifetime
- 1998-08-07 ES ES08004714T patent/ES2364703T3/es not_active Expired - Lifetime
- 1998-08-07 RU RU2000105905/14A patent/RU2221589C2/ru active
- 1998-08-07 PT PT08004714T patent/PT1930022E/pt unknown
- 1998-08-07 EP EP04022921A patent/EP1504764B1/en not_active Expired - Lifetime
- 1998-08-07 JP JP2000506994A patent/JP2001513333A/ja not_active Withdrawn
- 1998-08-07 AT AT08004714T patent/ATE511850T1/de active
- 1998-08-07 WO PCT/US1998/016439 patent/WO1999007405A1/en active Application Filing
- 1998-08-07 EP EP98939278A patent/EP0996460B1/en not_active Expired - Lifetime
- 1998-08-07 AT AT04022921T patent/ATE410179T1/de active
- 1998-08-07 EE EEP200000068A patent/EE04752B1/xx unknown
- 1998-08-07 PL PL384372A patent/PL201716B1/pl unknown
- 1998-08-07 DE DE69828614T patent/DE69828614T2/de not_active Expired - Lifetime
- 1998-08-07 PT PT98939278T patent/PT996460E/pt unknown
- 1998-08-07 CA CA002297736A patent/CA2297736A1/en not_active Abandoned
- 1998-08-07 IL IL13428898A patent/IL134288A0/xx unknown
- 1998-08-07 ES ES98939278T patent/ES2235350T3/es not_active Expired - Lifetime
- 1998-08-07 CZ CZ20000413A patent/CZ299768B6/cs not_active IP Right Cessation
- 1998-08-07 AT AT98939278T patent/ATE286742T1/de active
- 1998-08-07 TR TR2002/02323T patent/TR200202323T2/xx unknown
- 1998-08-07 ES ES04022921T patent/ES2311131T3/es not_active Expired - Lifetime
- 1998-08-07 AU AU87743/98A patent/AU739283B2/en not_active Expired
- 1998-08-07 HU HU0003547A patent/HU228900B1/hu unknown
- 1998-08-07 DK DK08004714.5T patent/DK1930022T3/da active
- 1998-08-07 TR TR2000/00374T patent/TR200000374T2/xx unknown
- 1998-08-07 PT PT04022921T patent/PT1504764E/pt unknown
- 1998-08-07 KR KR1020007001337A patent/KR100586202B1/ko not_active IP Right Cessation
-
1999
- 1999-08-02 US US09/365,695 patent/US6316601B1/en not_active Expired - Lifetime
-
2000
- 2000-01-30 IL IL134288A patent/IL134288A/en not_active IP Right Cessation
-
2001
- 2001-03-27 US US09/818,416 patent/US6692741B2/en not_active Expired - Lifetime
-
2004
- 2004-01-09 US US10/754,435 patent/US7150871B2/en not_active Expired - Lifetime
-
2006
- 2006-11-13 US US11/559,172 patent/US7544358B2/en not_active Expired - Fee Related
-
2008
- 2008-08-11 JP JP2008206826A patent/JP2009001587A/ja active Pending
-
2009
- 2009-01-08 CY CY20091100011T patent/CY1110462T1/el unknown
-
2011
- 2011-08-26 CY CY20111100822T patent/CY1111792T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE04752B1 (et) | Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine | |
HK1029513A1 (en) | Anticoagulant humanised antibodies against factor ix, for use in the treatment of thrombosis | |
NZ288883A (en) | Conjugates comprising coagulation factors | |
WO2004010947A3 (en) | Humanized antibodies against human 4-1bb | |
RS20060234A (en) | Fully human antibodies against human 4-1bb (cd137) | |
WO2003072036A3 (en) | Treatment methods using anti-cd22 antibodies | |
CY2013010I1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 | |
DK0807125T3 (da) | Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis | |
CY2010011I1 (el) | Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων | |
DE60121988D1 (de) | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln | |
PL401886A1 (pl) | Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal | |
EP0880597A4 (en) | THERAPEUTIC APPLICATIONS FOR MONOCLONAL ANTIBODY 5c8 ANTI-T-BAM (ANTI-CD40-L) | |
FI961083A (fi) | Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa | |
IT1271461B (it) | Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso. | |
WO2001005425A3 (en) | Combined preparations comprising daunorubicin derivatives and her2 antibodies | |
WO2003026692A3 (en) | Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex | |
TW200517124A (en) | Fully human antibodies against human 4-1BB | |
EP1411962A4 (en) | MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER | |
AU2001255537A1 (en) | Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs | |
ATE136469T1 (de) | Neue verwendung eines monoklonalen antikörpers | |
ZA986064B (en) | Ancrod-specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and their use. | |
EE9700021A (et) | Fibriinile mõju avaldav monoklooniline antikeha kasutamiseks tromboosivastases ravis, farmatseutilised kompositsioonid ja ravimaine | |
DK0919617T3 (da) | Monoklonale antistoffer mod humant MP52 | |
GEP20043233B (en) | Composition Containing Blocking Monoclonal Antibody VLA-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change of owner name | ||
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |